A study of a GLP-1 medicine, semaglutide, in people with Alzheimer's dementia (AD).
Recruiting now. Registry record last updated June 16, 2026.
- Who can join
- Adults 50 to 86, have Alzheimer's dementia (AD).
- What you take
- Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Alzheimer Dementia (AD).
Full scientific study title: Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease.
Who can join
Adults 50 to 86, have Alzheimer's dementia (AD). A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Diagnosis of probable Alzheimer disease according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria13.
- Male or female age 50 to 86 years
- MMSE between 16-26
- Albumin greater than or equal to 3.0 mg/dL
- White Blood Count (WBC) \>3,500/mm3; platelets \>100,000/mm3; hematocrit (HCT) \>32%.
Key exclusion criteria
- Any untreated bacterial, fungal or viral infection
- Renal dysfunction indicated by serum creatinine greater than 1.5 mg/dL
- Hepatic impairment indicated by Alanine aminotransferase level (ALT) and aspartate aminotransferase (AST) greater than two times normal
- Clinically significant pulmonary dysfunction, including a history of chronic pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\]) associated with functional limitation, or FEV₁ \< 75% of predicted for age and height when pulmonary function testing indicated to evaluate ongoing respiratory symptoms
- Clinically significant cardiac dysfunction, including a history of uncontrolled cardiac arrhythmias, prior cardiac tamponade, or unstable angina or myocardial infarction within 3 months prior to screening, or clinically significant abnormalities on baseline electrocardiogram (ECG). LVEF\< 40% in echocardiography if clinically indicated based on ongoing cardiac symptoms or abnormal ECG findings
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Texas1 site
- Houston Methodist Research InstituteHouston, Texas
Timeline
Started enrolling: July 2026. Expected completion: December 2029. Last updated on ClinicalTrials.gov: June 16, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
